07:00 , Apr 13, 2015 |  BC Week In Review  |  Company News

EUSA Pharma, Jazz Pharmaceuticals deal

Essex Bidco Ltd. acquired five approved specialty hospital products and related commercial infrastructure from Jazz for about $33 million in cash. Jazz gained rights to the products under its 2012 acquisition of EUSA Pharma Inc....
08:00 , Feb 2, 2015 |  BC Week In Review  |  Company News

Takeda Pharmaceuticals Co. Ltd. sales and marketing update

Takeda launched IV fomepizole in Japan to treat ethylene glycol and methanol poisoning. Takeda has exclusive, Japanese rights to develop and commercialize the product under a May 2011 deal with Paladin Labs Inc. , which...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Clinical News

Fomepizole regulatory update

Takeda said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA for IV fomepizole to treat ethylene glycol and methanol poisoning. Takeda has exclusive, Japanese rights to develop and commercialize the product under...
07:00 , May 16, 2011 |  BC Week In Review  |  Company News

Paladin, Takeda deal

Paladin granted Takeda exclusive, Japanese rights to develop and commercialize fomepizole to treat ethylene glycol and methanol poisoning. Paladin markets the small molecule inhibitor of alcohol dehydrogenase as Antizol in the U.S. and Canada for...
07:00 , Aug 18, 2008 |  BC Week In Review  |  Company News

Jazz, Paladin sales and marketing update

Paladin acquired worldwide rights to Jazz's Antizol fomepizole and Antizol-Vet. Antizol is approved to treat ethylene glycol or methanol poisoning. Antizol-Vet is approved to treat ethylene glycol poisoning in dogs. Paladin licensed Canadian rights to...
07:00 , Jul 21, 2008 |  BioCentury  |  Finance

Ebb & Flow

In the largest untranched biotech financing this year, genome sequencing company Pacific Biosciences (formerly Nanofluidics) raised $100 million last week in a series E round. The company now has raised $178 million since it was...
22:57 , Jul 16, 2008 |  BC Extra  |  Financial News

Jazz raises $26 million

Jazz (NASDAQ:JAZZ) raised $26 million in a registered direct offering of 3.8 million units at $6.76. Each unit consists of a share priced at $6.70, which is a 1% discount to Jazz's close of $6.75...
07:00 , Jun 4, 2007 |  BioCentury  |  Finance

Ebb & Flow

Biogen Idec...
07:00 , Mar 12, 2007 |  BioCentury  |  Finance

Ebb & Flow

Undaunted by the uncertainty following the market sell-off on Feb. 27, IPO hopefuls continue to make their way toward the market. Last week,...
08:00 , Mar 5, 2007 |  BioCentury  |  Strategy

Trans-Atlantic play

Backed by a $175 million infusion from investors, EUSA Pharma Inc. says last week's acquisition of specialty pharma company OPi S.A. will provide revenues, products and infrastructure that will serve as the European foundation for...